In “National trends in the utilization of androgen deprivation therapy for very low
risk prostate cancer,” the authors demonstrate a significant decline in the use of
primary androgen deprivation (pADT), for very low risk prostate cancer. By 2015, only
1.7% of men in this population received pADT, representing a furthering of trends
witnessed in the early 21st century, and which have been previously described.
1
,
2
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to UrologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Does primary androgen-deprivation therapy delay the receipt of secondary cancer therapy for localized prostate cancer?.Eur Urol. 2012; 62: 966
- Patterns of declining use and the adverse effect of primary androgen deprivation on all-cause mortality in elderly men with prostate cancer.Eur Urol. 2015; 68: 32
- National practice patterns and time trends in androgen ablation for localized prostate cancer.J Natl Cancer Inst. 2003; 95: 981
United States vs. TAP Pharmaceutical Products, Inc., D. Mass., 01CR10354 settlement, October 3, 2001. https://http://www.justice.gov/archive/opa/pr/2001/October/513civ.htm.
- Reimbursement policy and androgen-deprivation therapy for prostate cancer.N Engl J Med. 2010; 363: 1822
- Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer.J Urol. 2006; 176: 2443
- Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.J Clin Oncol. 2006; 24: 4448
- Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.J Natl Cancer Inst. 2007; 99:: 1516
- Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events.BJU Int. 2016; 118: 221
Article info
Publication history
Accepted:
February 6,
2019
Received:
December 7,
2018
Identification
Copyright
© 2019 Published by Elsevier Inc.
